
Product Manual


ViraBind™ AAV Purification Kit

Catalog Number

VPK-140

10 preps

FOR RESEARCH USE ONLY
Not for use in diagnostic procedures



CELL BIOLABS, INC.
Creating Solutions for Life Science Research

Introduction

The viral system includes vectors developed from retrovirus (RV), adenovirus (AdV), adeno-associated virus (AAV), lentivirus (LV), and herpes simplex virus (HSV). AAV belongs to the family of Parvoviridae, a group of viruses among the smallest of single-stranded and non-enveloped DNA viruses. There are eight different AAV serotypes reported to date.



Recombinant AAV-2 is the most common serotype used in gene delivery, and can be produced at high titers with a helper virus or Cell Biolabs' AAV Helper-Free System. AAV-2 can infect both dividing and non-dividing cells and can be maintained in the human host cell, creating the potential for long-term gene transfer. Because AAV-2 is a naturally defective virus, requiring provision of several factors in *trans* for productive infection, it is considered the safest viral vector to use. Recently a new vector, AAV-DJ, was developed using DNA family shuffling to create a hybrid capsid from 8 different AAV serotypes, resulting in a vector with significantly higher *in vitro* infection rates across a variety of cells and tissues.

Recombinant AAV-2 and AAV-DJ vectors can be purified by CsCl gradient ultracentrifugation, iodixanol discontinuous gradient ultracentrifugation, or high-performance liquid chromatography (HPLC). The most popular technique, CsCl ultracentrifugation, is time consuming process which may result in poor recovery and quality (nonviral protein contamination and a high ratio of genome copies versus infectious units).

ViraBind™ AAV Purification Kit does not involve ultracentrifugation. AAV-2 or AAV-DJ is first purified from viral supernatant with a single-step purification matrix, then further purified/concentrated with a centrifugal concentrator (see Assay Principle below). The entire procedure takes about 3 hours. Each preparation can handle one 150 mm dish or two 100 mm dishes, resulting in 100 µL of highly purified AAV-2 (Figure 1) or AAV-DJ with low ratio of genome copies versus infectious units.

ViraBind™ AAV Purification Kit provides an efficient system for quick purification of AAV-2 or AAV-DJ with high recovery (>60%). The highly purified and concentrated viruses can be used in primary cell infections and *in vivo* applications.

Assay Principle



**Pretreatment of
AAV Lysate with
ViraBind Reagent A
and B**

**Addition of AAV
Purification Matrix**



**Collect the
AAV/Purification
Matrix in a
conical tube**



**Elute the
Purified AAV**



**Concentrate the
Purified Fraction**

Related Products

1. AAV-100: 293AAV Cell Line
2. VPK-141: ViraBind™ AAV Purification Mega Kit
3. VPK-145: QuickTiter™ AAV Quantitation Kit
4. AAV-200: ViraDuctin™ AAV Transduction Kit
5. VPK-099: ViraBind™ Adenovirus Miniprep Kit
6. VPK-100: ViraBind™ Adenovirus Purification Kit
7. VPK-104: ViraBind™ Lentivirus Purification Kit

Kit Components

1. ViraBind™ AAV Reagent A (Part No. 314001): One 0.3 mL sterile tube.
2. ViraBind™ AAV Reagent B (Part No. 314002): One 1.5 mL sterile tube.
3. AAV Purification Matrix (Part No. 314003): Two 1.8 mL sterile tubes.
4. Purification Buffer (Part No. 314105): One 50 mL bottle.
5. Elution Buffer (Part No. 314106): One 10 mL bottle.
6. Centrifugal Concentrators (Part No. 309106): Pack of 10 units with 20 recovery tubes.

Materials Not Supplied

1. AAV Helper-Free System
2. Transfection Reagent
3. HEK 293 cells and cell culture growth medium
4. 15 mL conical tubes
5. Centrifuge (capable of 10,000 x g)

Storage

Store ViraBind™ AAV Reagent B and Centrifugal Concentrators at room temperature and all other kit components at 4°C until their expiration dates.

Safety Considerations

Remember that you will be working with samples containing infectious virus. Follow the recommended NIH guidelines for all materials containing BSL-2 organisms.

Preparation of rAAV-2 or rAAV-DJ Samples

The following procedure is suggested for one 15 cm dish or two 10 cm dishes and may be optimized to suit individual needs. Please refer to the user manual when using Cell Biolabs' AAV Helper-Free System or other packaging systems.

1. Use HEK 293 cells that have been passaged 2-3 times prior to transfection. Culture these cells until the monolayer is 70-80% confluent.
2. Cotransfect cells with the pAAV-RC, pHelper and your expression construct according to manufacturer's manual.
3. After 48-72 hrs, add 0.5 M EDTA to a final of 10 mM to the plate and incubate for 3 min at room temperature. Gently shake the culture plate several times and harvest all media, including cells, in a sterile tube.
Note: Trypsin may be substituted for EDTA in this step.
4. Centrifuge for 5 min at 3000 rpm to pellet the transfected cells. Resuspend the cell pellet in 2.5 mL of serum-free DMEM.
5. Subject the cell suspension to four rounds of freeze/thaw cycles by alternating the tubes between the dry ice-ethanol bath and the 37°C water bath.
6. Collect the AAV supernatant by centrifugation at 10,000 x g for 10 minutes. Discard the pellet.
7. (Optional) For AAV samples produced with a helper adenovirus, inactivate the helper adenovirus by incubation the sample at 56°C for 30 minutes. Collect the AAV supernatant by centrifugation at 10,000 x g for 10 minutes. Discard the pellet.
8. The viral supernatant can be stored at -80°C or immediately purified (see purification instructions below).

Protocol

I. Purification

The following procedure is written for purification and concentration of 2.5 mL of AAV supernatant. For AAV samples that are less than 2.5 mL, add serum-free DMEM to the final volume of 2.5 mL.

1. Add 25 µL of ViraBind™ AAV Reagent A to 2.5 mL of viral supernatant, mixing well.
2. Incubate for 30 minutes at 37°C.
3. Centrifuge the AAV supernatant for 15 minutes at 5,000 x g.
4. Carefully collect the supernatant and transfer to a new tube. Discard the pellet.
5. Incubate ViraBind™ AAV Reagent B for 30-60 minutes at 37°C to ensure Reagent B is dissolved. Add 125 µL of ViraBind™ AAV Reagent B to the ViraBind™ AAV Reagent A pretreated 2.5 mL of viral supernatant, mixing well.
6. Incubate for 30 minutes at 37°C.

7. Collect the AAV supernatant by centrifugation at 10,000 x g for 10 minutes. Discard the pellet.
8. Transfer the AAV supernatant to a clean 15 mL conical tube.
9. Resuspend the AAV Purification Matrix by inverting and shaking. Add 300 μ L of matrix to the centrifuged supernatant.
10. Mix the supernatant/matrix suspension at **room temperature** for 30 minutes on an orbital shaker. Do not allow more than 30 minutes and proceed immediately to step 11.
11. Pellet the Purification Matrix by centrifugation for 10 minutes at 1,000 rpm.
12. Carefully remove the supernatant and wash the Purification Matrix with 2.5 mL of Purification Buffer.
13. Repeat steps 11-12 once more.
14. Carefully remove the final wash.
15. Elute the purified AAV from the purification matrix by adding 0.5 mL of Elution Buffer.
16. Mix at 4°C for 10 minutes on an orbital shaker.
17. Collect the elution fraction by centrifugation for 10 minutes at 1,000 rpm.
18. Carefully remove the elution supernatant.

II. Final Buffer Exchange and Concentration

1. Assemble a Centrifugal Concentrator unit by inserting the sample reservoir into a recovery tube.



2. Apply 0.5 mL of the recovered AAV fraction (step 18 above) to the sample reservoir of the Centrifugal Concentrator. Cap the concentrator and place into a tabletop microcentrifuge. Centrifuge for 5 minutes at 2,000 x g. Flow through can be discarded.
3. Concentrate the AAV fraction until 100 μ L remains in the sample reservoir.
4. Add 400 μ L of 1X PBS, or desired final buffer, to the Concentrator and continue to centrifuge until 100 μ L remains. Repeat step 4 once more.
5. Finally, concentrate until the desired final volume.
6. Using a clean recovery tube, collect the concentrated AAV sample by inverting the sample reservoir into the tube and briefly centrifuging to collect all of the liquid.

Example of Results

The following figures demonstrate typical purification results. One should use the data below for reference only. This data should not be used to interpret actual results.





Figure 1: Purification of AAV2-GFP. AAV2-GFP was produced by a helper-free system in 293 cells. AAV supernatant was subjected to the purification steps. Samples from each fraction were used

to infect 293 cells, GFP positive cells were scored by counting after three days. A: AAV Supernatant; B: Flow through; C: 1st wash; D: Elution.




Figure 2: Electrophoretic Profile of Purified AAV2-GFP.

References

1. Rabinowitz, J, and Samulski, R. J. (1998) *Curr. Opin. Biotechnol.*, **9**, 470-475.
2. Summer ford, C., and Samulski, R. J. (1999) *Nat. Med.*, **5**, 587-588.
3. Clark, K., Liu, X., McGrath, J., and Johnson, P. (1999) *Hum. Gene Ther.*, **10**, 1031-1039.

Recent Product Citations

1. Tsuneoka, Y. et al. (2015). Distinct preoptic-BST nuclei dissociate paternal and infanticidal behavior in mice. *EMBO J.* doi:10.15252/embj.201591942.
2. Nishikawa, T. et al. (2015). Resetting the transcription factor network reverses terminal chronic hepatic failure. *J Clin Invest.* doi: 10.1172/JCI73137.
3. Stankowska, D. L. et al. (2015). Neuroprotective effects of transcription factor Brn3b in an ocular hypertension rat model of glaucoma. *Invest Ophthalmol Vis Sci.* **56**:893-907.
4. Inaba, Y. et al. (2014). Gadd34 regulates liver regeneration in hepatic steatosis. *Hepatology.* **6**:1343-1356.
5. Moshiri, F. et al. (2014). Inhibiting the oncogenic mir-221 by microRNA sponge: toward microRNA-based therapeutics for hepatocellular carcinoma. *Gastroenterol Hepatol Bed Bench.* **7**:43-54.
6. Inaba, Y. et al. (2014). Gadd34 regulates liver regeneration in hepatic steatosis. *Hepatology.* doi: 10.1002/hep.27619.
7. Rodriguez, J.P. et al. (2014). Abrogation of β -Catenin signaling in oligodendrocyte precursor cells reduces glial scarring and promotes axon regeneration after CNS injury. *J Neurosci.* **34**:10285-10297.

8. Uchida, S. et al. (2010). Early life stress enhances behavioral vulnerability to stress through the activation of REST4-mediated gene transcription in the medial prefrontal cortex of rodents. *J. Neurosci.* **30**:15007-15018.

Warranty

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS' sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

Contact Information

Cell Biolabs, Inc.
7758 Arjons Drive
San Diego, CA 92126
Worldwide: +1 858-271-6500
USA Toll-Free: 1-888-CBL-0505
E-mail: tech@cellbiolabs.com
www.cellbiolabs.com

©2007-2016: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.